Mini review · 30 Jul 2024
Conference abstractPublished 28 Jan 2019
MicroRNAs from bench to bedside
LSUHSC School of Medicine, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
MicroRNAs have recently been reported to be present in human blood, stably circulating under the aegis of protein and lipid carrier forms. While the origins and purpose of circulating miRNAs remain unclear, considerable efforts have been made toward evaluating their potential for use as a practical and informative disease biomarker. Published evidence suggests that the content and composition of circulating miRNA in healthy individuals may be distinctly altered among those with certain diseases, including cancer. Given the urgent need for improved screening tests for human cancer, we wished to investigate whether serum miRNA could be used in breast cancer patients as a novel diagnostic and prognostic marker. Thus, we procured serum samples from over 100 breast cancer patients at various stages of management (including at the time of diagnosis, after endocrine therapy but prior to surgery and following completion of all management). Our goal here was to identify whether a particular miRNA or panel of miRNAs is able to detect the presence of breast cancer and whether it is likely to respond to a particular course of treatment better than others. An RNA-seq analysis of some samples revealed multiple miRNAs were altered between breast cancer and control patients. In triple negative breast cancer (TNBC) patients, miR-223 and miR-23a (among others) were increased significantly, while miR-375 and miR-10b were decreased. Remarkably, these trends were reversed in the samples from the very same patients following treatment. The return of these cancer-associated miRNAs to normal levels in response to treatment raises the possibility that these miRNAs could be tumor-derived. In summary, we believe these results need further investigation, currently validating the current RNA-seq findings by qRT-PCR. Additionally, we wish to explore whether these miRNAs are associated with patient outcomes as we continue to monitor the progress of patients during follow up.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 2 Nov 2017
Designing long acting agonists and antagonists of glycoprotein hormones using site directed mutagenesis and gene transfer; from the bench to bedside
Conference abstract · 9 Jan 2017
A novel strategy for developing long acting recombinant proteins: From bench to bedside
Commentary · 11 Feb 2025
Role of Bioanalytical Methods in Personalized Medicine: From Bench to Bedside
Opinion · 30 Jan 2025
Innovative Strategies in Biomedical Research: From Bench to Bedside
More from this journal
The newest in Journal of Biotechnology & Biomaterials.
Editorial · 30 May 2025
Biocatalytic Conversion of Agricultural Waste into Value-Added Chemicals Using Engineered Microbial Systems
Editorial · 30 May 2025
3D Bioprinting of Vascularized Tissue Constructs Using Bioink-Embedded Endothelial Cells
Editorial · 30 May 2025
Development of Flexible Bioelectronic Interfaces for Real-Time Neural Signal Monitoring
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Biotechnology & Biomaterials
- SubjectBiochemistry & Biotechnology
- SubjectMaterials Science
- BylineArticles whose byline prints “Suresh K Alahari”
